Rogue Breast Tumor Proteins Point to Potential Drug Therapies
March 28, 2017
March 28, 2017
ST. LOUIS, March 28 -- The Washington University St. Louis School of Medicine issued the following news release:
For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker -- rogue proteins -- that may be driving cancer cells and also could be targeted with existing treatments.
If DN . . .
For patients with difficult-to-treat cancers, doctors increasingly rely on genomic testing of tumors to identify errors in the DNA that indicate a tumor can be targeted by existing therapies. But this approach overlooks another potential marker -- rogue proteins -- that may be driving cancer cells and also could be targeted with existing treatments.
If DN . . .